H century, gold was recommended for the treatment of epilepsy. Its rational medicinal use began in the early 1920’s when it was introduced as a treatment of tuberculosis [6]. Gold as an anti rheumatic agent was first reported in 1929 [7]. Gold and gold compounds are now mostly used for the treatment of various diseases including psoriasis, palindromic TA 02 web rheumatism, juvenilearthritis and discoid lupus erythematosus [8,9]. However, following the body’s extensive exposure to gold compounds, it can diffuse to various organs like liver, kidney and spleen. Skin irritation, mouth ulcers, nephrotoxicity, liver toxicity and blood disorders have been associated with prolonged exposure to gold compounds [10]. Currently gold complexes have gained considerable attention due to their strong antiproliferative[11?4] and antiangiogenic potential [10]. The spectrum of gold complexes with documented cell growth inhibiting SMER-28 properties include a large variety of different ligands attached to gold in the oxidation states +1 or +3, that is gold (I) and gold (III) 
compounds [15,16]. Gold (I) complexes proved to be unsuitable for clinical practice due to accompanying cardiotoxicity [17,18], while studies on gold (III) complexes are comparatively scarce [8]. Gold (III) bears homology to 
cisplatin as it is isoelectronic with platinum (II) and tetracoordinate gold (III) complexes have the same square-planar geometries as cisplatin [3]. Cisplatin [cis-diamminedichloroplatinum(II)] is one of the most widely employed drugs in cancer chemotherapy, discovered moreRenal and Hepatic Toxicity of a Gold (III) CompoundMaterials and MethodsThis study was carried out in Pathology Department, College of Medicine, University of Dammam in 2010?011. It was compartmentalized into two segments comprising acute toxicity and subacute toxicity studies. For both segments, Albino Wistar male rats (n = 42), weighing 200?50 gram were obtained from the College of Veterinary Medicine, King Faisal University, Al-Hassa, Saudi Arabia. They were placed in an animal house under standardized conditions, fed standard chow and exposed to an optimized environment one week before the start of the experiment.Figure 1. Dichlorido(ethylenediamine)-aurate(III) ion. doi:10.1371/journal.pone.0051889.gthan 40 years ago [13], and it became the first FDA-approved platinum anticancer compound in 1978 [19]. Its effectiveness in solid tumoral lesions is markedly hampered by severe toxic side effects comprising predominantly nephrotoxicity [20,21], development of tumor 1326631 resistance[22?5] and occurrence of secondary malignancies [3,12,14] that contributes a high treatment failure ratio in clinical management. Current studies aim towards designing newer compounds showing enhanced anti-proliferative potential and less associated toxicity than cisplatin. In this regards, gold (III) complexes with various ligands like Au , Au or Au bonds are being extensively investigated for their bioactivities as antiproliferative agents [26] and simultaneously new combinations of complexes are being developed. Milovanovic et al have studied the cytotoxicity studies of [Au(en)Cl2]+ and [Au(SMC)Cl2]+ where SMC = Smethyl-L-cysteine and [Au(DMSO)2Cl2]+ (DMSO = dimethyl sulphoxide). They concluded that gold (III) complexes are much faster to react with nucleophiles compare to Pt(II) complexes. They also demonstrated that gold (III) complexes exhibit relevant cytotoxic properties when tested on chronic lymphocytic leukemia cells (CLL). This.H century, gold was recommended for the treatment of epilepsy. Its rational medicinal use began in the early 1920’s when it was introduced as a treatment of tuberculosis [6]. Gold as an anti rheumatic agent was first reported in 1929 [7]. Gold and gold compounds are now mostly used for the treatment of various diseases including psoriasis, palindromic rheumatism, juvenilearthritis and discoid lupus erythematosus [8,9]. However, following the body’s extensive exposure to gold compounds, it can diffuse to various organs like liver, kidney and spleen. Skin irritation, mouth ulcers, nephrotoxicity, liver toxicity and blood disorders have been associated with prolonged exposure to gold compounds [10]. Currently gold complexes have gained considerable attention due to their strong antiproliferative[11?4] and antiangiogenic potential [10]. The spectrum of gold complexes with documented cell growth inhibiting properties include a large variety of different ligands attached to gold in the oxidation states +1 or +3, that is gold (I) and gold (III) compounds [15,16]. Gold (I) complexes proved to be unsuitable for clinical practice due to accompanying cardiotoxicity [17,18], while studies on gold (III) complexes are comparatively scarce [8]. Gold (III) bears homology to cisplatin as it is isoelectronic with platinum (II) and tetracoordinate gold (III) complexes have the same square-planar geometries as cisplatin [3]. Cisplatin [cis-diamminedichloroplatinum(II)] is one of the most widely employed drugs in cancer chemotherapy, discovered moreRenal and Hepatic Toxicity of a Gold (III) CompoundMaterials and MethodsThis study was carried out in Pathology Department, College of Medicine, University of Dammam in 2010?011. It was compartmentalized into two segments comprising acute toxicity and subacute toxicity studies. For both segments, Albino Wistar male rats (n = 42), weighing 200?50 gram were obtained from the College of Veterinary Medicine, King Faisal University, Al-Hassa, Saudi Arabia. They were placed in an animal house under standardized conditions, fed standard chow and exposed to an optimized environment one week before the start of the experiment.Figure 1. Dichlorido(ethylenediamine)-aurate(III) ion. doi:10.1371/journal.pone.0051889.gthan 40 years ago [13], and it became the first FDA-approved platinum anticancer compound in 1978 [19]. Its effectiveness in solid tumoral lesions is markedly hampered by severe toxic side effects comprising predominantly nephrotoxicity [20,21], development of tumor 1326631 resistance[22?5] and occurrence of secondary malignancies [3,12,14] that contributes a high treatment failure ratio in clinical management. Current studies aim towards designing newer compounds showing enhanced anti-proliferative potential and less associated toxicity than cisplatin. In this regards, gold (III) complexes with various ligands like Au , Au or Au bonds are being extensively investigated for their bioactivities as antiproliferative agents [26] and simultaneously new combinations of complexes are being developed. Milovanovic et al have studied the cytotoxicity studies of [Au(en)Cl2]+ and [Au(SMC)Cl2]+ where SMC = Smethyl-L-cysteine and [Au(DMSO)2Cl2]+ (DMSO = dimethyl sulphoxide). They concluded that gold (III) complexes are much faster to react with nucleophiles compare to Pt(II) complexes. They also demonstrated that gold (III) complexes exhibit relevant cytotoxic properties when tested on chronic lymphocytic leukemia cells (CLL). This.